Ikena Oncology Completes Merger with Inmagene Biopharmaceuticals

Ikena Oncology ( (IKNA) ) has issued an announcement.

On July 25, 2025, Inmagene Biopharmaceuticals announced the completion of its merger with Ikena Oncology, forming ImageneBio, Inc., which will trade on Nasdaq under the ticker ‘IMA’ starting July 28, 2025. The merger, accompanied by a $75 million private placement, positions ImageneBio to advance the development of IMG-007, a promising treatment for atopic dermatitis, with a Phase 2b trial ongoing and topline results expected in late 2026.

The most recent analyst rating on (IKNA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ikena Oncology stock, see the IKNA Stock Forecast page.

Spark’s Take on IKNA Stock

According to Spark, TipRanks’ AI Analyst, IKNA is a Neutral.

Ikena Oncology’s overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.

To see Spark’s full report on IKNA stock, click here.

More about Ikena Oncology

ImageneBio, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for immunological/autoimmune and inflammatory diseases. The company’s lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody currently in Phase 2b clinical trials for atopic dermatitis.

Average Trading Volume: 202,662

Technical Sentiment Signal: Sell

Current Market Cap: $66.11M

For an in-depth examination of IKNA stock, go to TipRanks’ Overview page.